Eyelash Growth from Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Objective: To determine whether bimatoprost (Lumigan, Allergan Inc., Irvine, CA) causes increased lash length when used in gel suspension applied to the base of the eyelashes. Design: Randomized controlled trial. Participants: Nineteen subjects were enrolled. Methods: Subjects recruited from the Bascom Palmer Eye Institute were screened, and those who met inclusion criteria were enrolled. Each participant received 2 vials of gel suspension, which contained bimatoprost and normal saline, respectively, each mixed 1:1 with Gonak gel (Akorn Inc., Lake Forest, IL) and labeled "right eye" and "left eye" according to randomization. The suspension was applied to the upper eyelid eyelashes every evening on the designated eye for 6 weeks. Main Outcome Measures: Lash length was measured with a caliper at enrollment, at weekly intervals during the application of the gel, and at 1 and 3 months after discontinuation of its use. Visual acuity, ocular symptoms, intraocular pressure, and photographs were documented at these same intervals. Results: The mean eyelash growth from baseline in the bimatoprost group was 2.0 mm versus a mean of 1.1 mm in the placebo group, which was a statistically significant difference (P=0.009). The average intraocular pressure decreased equally in both groups (2 mmHg). No change in visual acuity or iris discoloration was noted in any of the subjects. Conclusions: Our data showed an increase in eyelash length with the use of bimatoprost in gel suspension, suggesting the product's eyelash-lengthening properties. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Original languageEnglish
Pages (from-to)1024-1031
Number of pages8
JournalOphthalmology
Volume117
Issue number5
DOIs
StatePublished - May 1 2010

Fingerprint

Eyelashes
Suspensions
Gels
Growth
Intraocular Pressure
Visual Acuity
Disclosure
Iris
Eyelids
Lakes
Random Allocation
Randomized Controlled Trials
Placebos
Outcome Assessment (Health Care)
Bimatoprost

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Eyelash Growth from Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes. / Wester, Sara; Lee, Wendy; Shi, Wei.

In: Ophthalmology, Vol. 117, No. 5, 01.05.2010, p. 1024-1031.

Research output: Contribution to journalArticle

@article{d6787536613c47be91c81e149e406e71,
title = "Eyelash Growth from Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes",
abstract = "Objective: To determine whether bimatoprost (Lumigan, Allergan Inc., Irvine, CA) causes increased lash length when used in gel suspension applied to the base of the eyelashes. Design: Randomized controlled trial. Participants: Nineteen subjects were enrolled. Methods: Subjects recruited from the Bascom Palmer Eye Institute were screened, and those who met inclusion criteria were enrolled. Each participant received 2 vials of gel suspension, which contained bimatoprost and normal saline, respectively, each mixed 1:1 with Gonak gel (Akorn Inc., Lake Forest, IL) and labeled {"}right eye{"} and {"}left eye{"} according to randomization. The suspension was applied to the upper eyelid eyelashes every evening on the designated eye for 6 weeks. Main Outcome Measures: Lash length was measured with a caliper at enrollment, at weekly intervals during the application of the gel, and at 1 and 3 months after discontinuation of its use. Visual acuity, ocular symptoms, intraocular pressure, and photographs were documented at these same intervals. Results: The mean eyelash growth from baseline in the bimatoprost group was 2.0 mm versus a mean of 1.1 mm in the placebo group, which was a statistically significant difference (P=0.009). The average intraocular pressure decreased equally in both groups (2 mmHg). No change in visual acuity or iris discoloration was noted in any of the subjects. Conclusions: Our data showed an increase in eyelash length with the use of bimatoprost in gel suspension, suggesting the product's eyelash-lengthening properties. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.",
author = "Sara Wester and Wendy Lee and Wei Shi",
year = "2010",
month = "5",
day = "1",
doi = "10.1016/j.ophtha.2009.10.017",
language = "English",
volume = "117",
pages = "1024--1031",
journal = "Ophthalmology",
issn = "0161-6420",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Eyelash Growth from Application of Bimatoprost in Gel Suspension to the Base of the Eyelashes

AU - Wester, Sara

AU - Lee, Wendy

AU - Shi, Wei

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Objective: To determine whether bimatoprost (Lumigan, Allergan Inc., Irvine, CA) causes increased lash length when used in gel suspension applied to the base of the eyelashes. Design: Randomized controlled trial. Participants: Nineteen subjects were enrolled. Methods: Subjects recruited from the Bascom Palmer Eye Institute were screened, and those who met inclusion criteria were enrolled. Each participant received 2 vials of gel suspension, which contained bimatoprost and normal saline, respectively, each mixed 1:1 with Gonak gel (Akorn Inc., Lake Forest, IL) and labeled "right eye" and "left eye" according to randomization. The suspension was applied to the upper eyelid eyelashes every evening on the designated eye for 6 weeks. Main Outcome Measures: Lash length was measured with a caliper at enrollment, at weekly intervals during the application of the gel, and at 1 and 3 months after discontinuation of its use. Visual acuity, ocular symptoms, intraocular pressure, and photographs were documented at these same intervals. Results: The mean eyelash growth from baseline in the bimatoprost group was 2.0 mm versus a mean of 1.1 mm in the placebo group, which was a statistically significant difference (P=0.009). The average intraocular pressure decreased equally in both groups (2 mmHg). No change in visual acuity or iris discoloration was noted in any of the subjects. Conclusions: Our data showed an increase in eyelash length with the use of bimatoprost in gel suspension, suggesting the product's eyelash-lengthening properties. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

AB - Objective: To determine whether bimatoprost (Lumigan, Allergan Inc., Irvine, CA) causes increased lash length when used in gel suspension applied to the base of the eyelashes. Design: Randomized controlled trial. Participants: Nineteen subjects were enrolled. Methods: Subjects recruited from the Bascom Palmer Eye Institute were screened, and those who met inclusion criteria were enrolled. Each participant received 2 vials of gel suspension, which contained bimatoprost and normal saline, respectively, each mixed 1:1 with Gonak gel (Akorn Inc., Lake Forest, IL) and labeled "right eye" and "left eye" according to randomization. The suspension was applied to the upper eyelid eyelashes every evening on the designated eye for 6 weeks. Main Outcome Measures: Lash length was measured with a caliper at enrollment, at weekly intervals during the application of the gel, and at 1 and 3 months after discontinuation of its use. Visual acuity, ocular symptoms, intraocular pressure, and photographs were documented at these same intervals. Results: The mean eyelash growth from baseline in the bimatoprost group was 2.0 mm versus a mean of 1.1 mm in the placebo group, which was a statistically significant difference (P=0.009). The average intraocular pressure decreased equally in both groups (2 mmHg). No change in visual acuity or iris discoloration was noted in any of the subjects. Conclusions: Our data showed an increase in eyelash length with the use of bimatoprost in gel suspension, suggesting the product's eyelash-lengthening properties. Financial Disclosure(s): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

UR - http://www.scopus.com/inward/record.url?scp=77951623319&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951623319&partnerID=8YFLogxK

U2 - 10.1016/j.ophtha.2009.10.017

DO - 10.1016/j.ophtha.2009.10.017

M3 - Article

C2 - 20163864

AN - SCOPUS:77951623319

VL - 117

SP - 1024

EP - 1031

JO - Ophthalmology

JF - Ophthalmology

SN - 0161-6420

IS - 5

ER -